Recent Updates
Recently added Catalysts
LGVN Positive Sentiment Score: 65/100

Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Thursday, May 2, 2024 1 min read
Key Takeaway: Longeveron Inc. (NASDAQ: LGVN) is set to report its first quarter 2024 financial results on May 14, 2024, following the close of U.S. markets. The announcement also includes details about a conference call and webcast scheduled for later that day. The company, focused on regenerative medicines, will provide a business update during the call. Their leading investigational product, Lomecel-B, has the potential to address various health conditions, including Alzheimer’s disease and age-related frailty.

Market Sentiment Analysis

POSITIVE FACTORS

  • Longeveron is actively advancing its pipeline of regenerative medicines.
  • The upcoming conference call indicates transparency and engagement with investors.
  • Lomecel-B shows promise for addressing multiple medical needs and conditions.

Full Press Release Details

MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 5:00 p.m. ET.
Conference Call Details:
Conference Call Number: 1.877.407.0789
Conference ID: 13745868
Call me TM Feature: Click Here
Webcast: Click Here
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

Tags

Frequently Asked Questions

When will Longeveron report Q1 2024 financial results?

Longeveron will report Q1 2024 financial results on May 14, 2024.

What is Lomecel-B™ developed by Longeveron?

Lomecel-B™ is an allogeneic MSC therapy aimed at regenerative medicine.

What diseases is Longeveron targeting with its research?

Longeveron is targeting hypoplastic left heart syndrome, Alzheimer's, and frailty.

How can I access Longeveron's conference call?

Dial 1.877.407.0789 and use conference ID 13745868 to access the call.

Where can I find the archived webcast of the conference?

The archived webcast will be available on Longeveron's website post-conference.

Tags: LGVN Viatris Investor Conferences Healthcare Longeveron Lomecel-B regenerative medicine Alzheimer's disease
Last updated: May 2, 2024